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ABSTRACT 
Onur Dagliyan: Engineered control of protein activity in living cells 
(Under the directions of Nikolay V. Dokholyan and Klaus M. Hahn) 
 
Cell behavior results from the precise orchestration of molecular activity in time and 
space. The need to understand dynamics of proteins in the context of living systems has 
recently led to the development of a remarkable suite of protein ‘switches’, engineered 
domains and other approaches that cause proteins to respond to small molecules or light, 
enabling us to control the spatiotemporal dynamics of protein-protein interactions, 
posttranslational modifications, conformational change, and subcellular localization. 
However, existing methods suffer from many disadvantages including increased basal 
activity before protein activation, slow kinetics, difficulty in delivery and expression, and 
inefficient activation. This dissertation describes two strategies to manipulate protein activity 
to interrogate the role of the protein of interest in cell motility. In the first study, I developed 
a ligand-controlled switch to manipulate activities of various kinases dynamically. In the 
second study, I developed a novel and generalizable approach to control protein activity by 
splitting target proteins and regulating their reassembly using a ligand or light. Both methods 
were used to investigate the dynamics of proteins including kinases and guanine nucleotide 
exchange factors in cell motility. 
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CHAPTER 1: GENETICALLY ENCODED TOOLS TO CONTROL PROTEIN 
ACTIVITY IN LIVING CELLS 
 
A cell can use the same proteins to produce essentially opposing cell behaviors, by 
controlling the precise localization and kinetics of protein activities (e.g. the same kinase 
involved in both apoptosis and proliferation (1)).  The need to understand molecular dynamics 
in the context of living systems has recently led to the development of a remarkable suite of 
protein ‘switches’, engineered domains and other approaches that cause proteins to respond to 
small molecules or light, enabling us to control the spatiotemporal dynamics of protein-protein 
interactions, posttranslational modifications, conformational change, protein stability, and 
subcellular localization. Here I provide an overview of genetically encoded tools that have 
been successfully used in cells, organized around design concepts. I will discuss naturally 
occurring small molecule or light sensitive proteins that provide the building blocks for most 
of the designs. 
 
Control of protein localization and interaction 
In many cases, the cell controls protein interactions by restricting proteins to specific 
subcellular regions, a mode of regulation that can be readily engineered for artificial regulation 
by small molecules.  Pioneering work by Picard et al. (2) , controlling transcription using rapid 
hormone-induced nuclear translocation of DNA-binding domains, paved the way. However, it 
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was not widely adopted because of side effects and activity in the absence of hormone. A 
robust and broadly applied approach harnesses the ability of the small molecule rapamycin to 
induce tight dimerization of two proteins, FKBP12 and FKBP12-rapamycin binding protein 
(FRB) (3, 4). The proteins to be controlled are either attached to FKBP12 and FRB so that 
rapamycin addition drives their dimerization, or one of the rapamycin-binding proteins is 
anchored at a particular subcellular location (e.g. the plasma membrane), so that small 
molecule addition drives the other protein to that location (5) (Figure 1.1A).   
 
Protein of interest (POI) is recruited to the region of interest to interact with its effector by 
dimerization of green and blue proteins in the presence of a small molecule (A) or light (B). 
Chemical dimerizers include 12 kDa FK506 binding protein (FKBP12):rapamycin 
(RAPA):FRB, pyrabactin resistance (PYR)/PYR1-like (PYL)/regulatory component:abscisic 
acid(ABA):protein phosphatase type 2Cs (PP2C),  gibberellin insensitive (GAI): gibberellin 
(GA3): gibberellin insensitive dwarf1 (GID1). Optical dimerizers include light, oxygen, 
voltage (LOV):GIGANTAE (GI), cryptochrome (CRY)-cryptochrome interacting basic helix-
loop-helix (CIB), and  phytochrome B (PhyB):phytochrome interacting factor (PIF) pairs. (C) 
POI-CRY forms clusters upon blue light exposure to amplify the signaling activity.  (D) POI 
is retracted from its localization site into large protein assembly, resulting in inhibition of 
activity. 
Figure 1.1.   Control of protein localization and protein-protein interaction. 
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Chemical dimerizers have provided a practical means to study a diverse array of 
cellular phenomena. In Rho-GTPase biology, these include phagocytosis upon recruitment of 
Rac1 to the plasma membrane (6), Rac1-triggered local positive feedbacks in polarized cells 
(7, 8), and Cdc42-induced protrusions (9). Other applications include control of clathrin-
mediated endocytosis and recycling (10), control of endosome morphology and selective cargo 
sorting (11), calcium-induced activation of a  Ca2+ channel (12, 13), phosphoinositide 
regulation of ion conductance (14),  actin dynamics (15), mitogen-activated kinase ERK 
activity at focal adhesions (16), and the collective behaviors of myosinVa and kinesin motors 
(17). These studies highlight the robustness and broad applicability of chemical dimerizers for 
rapid and sustained activation of protein activity. 
Improvements have included the development of different small molecule/protein 
systems for orthogonal control, and modified small molecules that avoid the specific side 
effects of each system (18). Orthogonal control has been achieved through dimerization of the 
proteins pyrabactin resistance 1 and protein phosphatase type 2C (PP2C) using abscisic acid 
(19), and with gibberellin-induced dimerization of receptor gibberellin insensitive dwarf1 
(GID1) and gibberellin insensitive (GAI) (20). In one example of orthogonal control, histone 
modification by methylated histone-dependent silencer heterochromatin protein (HP1α) and 
transcriptional activator VP16 were controlled in the same cells by combining the rapamycin 
and abscisic acid systems (21). Remarkably, removal of the small molecules did not change 
the state of histone modification, revealing heritable transmission of histone posttranslational 
modifications. 
The precision with which activation kinetics can be controlled using chemical 
dimerization is limited by the rate at which the small molecules enter the cell, and their 
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diffusion once inside. In animals or complex multicellular systems, the kinetics of delivery to 
the site of action is also a factor. Spatial resolution is limited by diffusion of the small molecule 
as well. Therefore, investigators usually target specific cells or tissue regions, rather than 
subcellular regions. Subcellular localization of activity has been achieved by producing 
gradients of rapamycin concentration across cells (8). Spatial and temporal resolution has been 
improved by generating ‘caged’ derivatives of rapamycin, which are inert until irradiated (22, 
23). Such molecules can build up at the site of action before they are rapidly triggered with 
light. Importantly, activation using rapamycin is rapid, but the dimerization they induce is 
essentially irreversible. 
Optogenetics, the use of genetically encoded proteins to control cell behavior with 
light, offers important advantages over chemical dimerizers, including rapid activation with 
the spatial resolution of the light microscope. Optogenetics began with the use of light-gated 
ion channels expressed in specific neuron populations (24). In an outpouring of imaginative 
work over the last five years, this has been extended to non-channel proteins using a number 
of different light-responsive proteins (Figure 1.1B). In addition to outstanding temporal and 
spatial resolution, optogenetics offers reversible activation, and kinetics that can be adjusted 
using point mutations in the light receptors. An important limitation is the poor penetration and 
dispersion of light in animals, where chemical triggers can provide access. 
Plant proteins that dimerize in response to light have been important in the evolution 
of optogenetics. Interaction between the GTPase Cdc42 and its downstream effector WASP 
was induced in vitro by coupling these two proteins to the light-responsive proteins 
Phytochrome B (PhyB) and partner interacting factor (PIF) (25, 26). In order to prevent Cdc42-
WASP interaction in the dark, an inactive mutant of Cdc42 was used; despite the mutation, 
 20 
light-induced dimerization was sufficient to generate WASP activity. In living cells, the 
PhyB:PIF pair has been used to control the membrane translocation of guanine nucleotide 
exchange factors (GEFs), which activated downstream GTPases and produced changes in cell 
morphology (27, 28). PhyB and PIF dimerize in response to red light (approximately 650 nm) 
and dissociate in far-red light (approximately 750 nm). Different responses to two 
wavelengths, and the very rapid kinetics of association and dissociation, enabled unusually 
precise control of protein activity. Different regions of the cell were bathed in different colors 
of light; molecules that diffused across the boundary between regions changed state in less 
than a second (27). Using automated feedback control, precise levels of signaling interactions 
could be maintained (28).  By photo-activating Ras while monitoring nuclear translocation of 
ERK, Toettcher et al. showed that the kinetics of Ras activation affected differential interaction 
with downstream pathways.  Phy and PIF have been used to drive proteins to different 
subcellular locations in yeast, including the plasma membrane, nucleus, bud neck, myosin ring, 
peroxisome, endosome, and spindle pole body (29). As with most photoresponsive proteins, 
light absorption is due to a small molecule cofactor. PhyB and PIF are plant proteins that do 
not exist in yeast or mammalian cells. This necessitates either the addition of cell-permeable 
cofactor phycocyanobilin to the cell media or in situ synthesis of phycocyanobilin (30). 
Another pair of plant proteins that dimerize upon irradiation, Cryptochrome (CRY) and 
crytochrome-interacting basic helix-loop-helix protein (CIB), have found widespread use, 
attesting to their versatility and robust response. CRY absorbs blue light (approximately 400-
500 nm) through a flavin adenine dinucleotide cofactor located in an N-terminal DNA 
photolyase homology domain (PHR).  Unlike the cofactor of PhyB, this flavin is incorporated 
simply upon expression, from yeast to mammals. Similar to the PhyB:PIF system, CRY:CIB 
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can be turned on in less than a second, but the half-life of CRY:CIB return to the dark state is 
substantially slower, approximately 5.5 minutes. 
Translocation of proteins using CRY:CIB dimerizer has been widely used to control 
various cellular processes, including nuclear translocation of transcription factors and 
movement of GTPases to the plasma membrane (31), local production of phosphoinositide (32, 
33), transcription and epigenetic regulation (34), and G protein signaling mediating cell 
migration (35). 
The light, oxygen, or voltage (LOV) domain, from Zeitlupe or Phototropin family 
proteins, responds to light using a different mechanism than the dimerizer proteins described 
above. This has been exploited both to control dimerization, and for other optogenetic designs 
to be discussed in later sections. Like Cry:CIB, the LOV domain uses a flavin chromophore 
that requires no exogenous cofactor addition, and responds to light between 400 and 500 nm 
(36). The LOV2 domain of the protein flavin-binding/kelch repeat/F-box (FKF1) interacts with 
the protein gigantea (GI) to control flowering of Arabidopsis thaliana (37, 38). This was 
exploited to produce optogenetic dimerizers LOV2 and GI, used to control transcription of 
luciferase (38, 39), and recruitment of Rac1 to the plasma membrane (38).  Rac1 remained in 
the membrane approximately 1.5 hours due to the slow deactivation kinetics of this system. 
Proteins that oligomerize (rather than dimerize) in response to light have been used to 
concentrate proteins in specific subcellular locations, increasing their local activity. CRY 
forms oligomeric “photobodies” in response to blue light (Figure 1.1C). Wend et al. directly 
compared CRY oligomerization versus CRY:CIB dimerization in activation of the kinase C-
RAF (40), and found that oligomerization was more efficient at producing phosphorylation of 
ERK1/2 by MEK1/2, downstream of C-RAF. This approach has been used to locally 
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concentrate β-catenin, Rac1, RhoA, and DNA damage checkpoint protein TopBP1 in living 
cells (41, 42). 
Cry2-mediated protein clustering has also been used to inhibit protein activity, through 
reversible sequestration of the target protein away from its site of action (Figure 1.1D). 
Ca2+/calmodulin-dependent protein kinase IIα (CaMKIIα) forms oligomers consisting of 
twelve subunits. Each subunit of CaMKII was fused to CIB1, and target proteins were fused 
to CRY2. Upon blue light irradiation, the proteins fused to Cry2 were trapped in CaMKIIα-
CIB complexes. To provide broader applicability, CRY2 was fused to an anti-GFP antibody 
fragment potentially enabling inactivation of any proteins fused to GFP. 
Proteins under control of optogenetic or chemogenetic dimerizers often show some 
level of activation even before they are turned on. This can occur because the switch is in 
equilibrium between the on and off states, with light simply shifting the equilibrium. 
Alternately, even the inactive conformation may have weak affinity for a downstream target. 
Such ‘leakiness’ can be a serious problem, especially when the cell is sensitive to relatively 
small changes in the concentration of active protein. The problem can be ameliorated by 
engineering the protein to maximize the difference between on and off activity levels. 
Expression level must often be controlled.  In a rapamycin-regulated system, Kapp et al. 
approached this problem by altering the binding interface between the two proteins whose 
interaction was being controlled.  Cdc42 and its upstream activator intersectin were engineered 
so they could only bind to one another, and not to their endogenous counterparts. The 
engineered Cdc42 was minimally activated by endogenous intersectin, leading to more robust 
Cdc42-induced effects (filopodia and lamellipodia), presumably because the cell had not 
compensated for the overexpressed Cdc42 (43).  
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Control of active site exposure  
While designing orthogonal pairs offer reduced background activity, broad application 
of such systems requires extensive protein engineering. As opposed to control of protein 
localization and interactions, modulation of protein conformation may offer a complete 
repressed activity in basal conditions. One way to keep protein inactive before the stimulation, 
termed as caging, is to block active site sterically with ligand or light controlled domains 
(Figure 1.2). In a chemogenetic approach, each terminal of VCA domain of WASP protein was 
fused to PDZ domain and its peptide ligand (Figure 1.2). The length of the linkers between the 
domains and peptide were designed long enough to keep the PDZ-peptide bound complex to 
block the VCA active site. Addition of exogenous PDZ ligand that has a higher affinity than 
the intramolecular peptide disassociated PDZ ligand from its intramolecular peptide, resulting 
in exposure of VCA active site (44). By systematically changing the number and affinity of 
ligand binding domain with its intramolecular peptide, an ultrasensitive version of a similar 
switch was also built (45). Similarly, PDZ domain and its intramolecular peptide were fused 
to the terminals of catalytic domain of Rho GEFs Intersectin and Trio. Microinjection of 
protein kinase A (PKA) that phosphorylates intramolecular peptide, uncaged the catalytic 
domain (46). An alternative approach was developed using antiapoptotic protein Bcl-xL, its 
intramolecular peptide BH3 and its exogenous competitive cell permeable small molecule 
ligand (47).  
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(A) Active site accessibility is controlled using PDZ domain (green) and its binding peptide 
(light purple). An exogenous peptide (dark purple) which has a higher affinity to PDZ is used 
to diassosiacte PDZ-peptide interaction, resulting an accessible active site (B) A similar 
strategy was employed using light-sensitive LOV2 (L) and Dronpa (D) proteins.  
 
 
Optogenetic control of active site exposure was first achieved with LOV2 domain (48). 
Fusion of LOV2 to the amino terminal of the Rac1 blocked the access of effectors to the active 
site of Rac1 (Figure 1.2B). Light absorption of cofactor flavin of LOV2 and consequent 
structural propagation causes unfolding of C-terminal helix Jα that leads the exposure of Rac1 
active site. Using this photoactivatable Rac1 (PA-Rac1), it was revealed that localized 
activation of Rac1 is sufficient to direct the migration of fibroblasts (48), neutrophils in 
zebrafish (49), and entire border cell group in Drosophila (50). Similar steric caging with 
LOV2 was also successfully applied to Caspase-7 (51), stromal interaction molecule 1 (52), 
endonuclease PvuII (53), omithine decarboxylase-like degradation sequence (54), formin 
Figure 1.2.   Chemogenetic and optogenetic control of active site exposure. 
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mDia  (55, 56). Natural DNA binding proteins that include LOV2 were engineered to control 
gene transcription (57, 58). 
Depending on the location of amino terminal and the active site, simple fusion of LOV2 
to the protein may not be sufficient to block the active site. To overcome this problem, 
photoactivatable protein Dronpa proteins were fused to each terminal of catalytic domains of 
GEF intersectin and hepatitis C virus protease (Figure 1.2). Upon exposure of light at 390 nm, 
Dronpa domains at the terminals associated and blocked the active site. Shifting the light to 
490 nm, caused dissociation of the domains and expose the active site (59). Since Dronpa is 
also a GFP-like fluorescent protein, the approach includes the simultaneous visualization of 
protein localization. 
In addition to proteins, short peptides were also caged using LOV2 domain. Such 
approach can be useful to control activity of endogenous proteins. Small peptides were 
embedded into the Jα helix of LOV2. Unfolding of Jα helix render the peptides exposed so 
they are able to interact with targets. Caged peptides were used to recruit proteins to plasma 
membrane (60) and nucleus (61).  Vinculin binding peptide ipaA, and protease delivery protein 
SspB binding protein SsrA were caged using molecular modeling (62). Inhibitory peptides of 
kinases including PKA, MLCK were successfully caged with LOV2 (63). 
 
Allosteric control through domain insertion 
 While steric caging was successfully applied to several proteins, this approach is 
dependent on terminal location and often required extensive truncations in large proteins to 
ensure fused domains block the access of the interacting substrate or protein. Instead of sensory 
domain fusion to the termini, domain insertion into the allosteric regions of the host protein 
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offers a robust way to control protein activity. In some exceptional cases in which terminal 
region functions as an allosteric region, end to end fusion of regulatory domain and the host 
protein can render the protein allosterically controlled.  For example, fusion of LOV2 to N-
terminus of truncated transcription factor trp repressor can regulate DNA binding at a remote 
site in a light dependent manner (64).  Similarly, catalytic domain of an unregulated 3-deoxy-
D-arabino-heptulosonate 7-phosphate synthase was simply fused to a ligand binding ACT 
domain to achieve an allosteric chimera (65). However, in the majority of signaling proteins, 
termini region intrinsically has insignificant effect on the activity that makes the allosteric 
control through end-to-end fusion infeasible. 
        
 
 
(A) Insertable FKBP (iFKBP) domain is inserted into an allosteric site of the kinase domain 
(gray). This construct is destabilized, as iFKBP is not stable alone. Rapamycin binds to both 
iFKBP and co-expressed FRB protein, resulting reactivation of the kinase. S denotes the 
substrate.    
 
 
Domain insertion strategy offers controlling active site conformation or dynamics 
independent from terminal locations. Considering that nine percent of all multi domain proteins 
Figure 1.3.   Rapamycin-regulatable (RapR) kinase approach 
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have naturally inserted domains (66), and many proteins permit large domain insertions (67, 
68), this approach may offer broad applicability. FKBP12 domain was one of the first proteins 
used as a non-native regulatory domain. FKBP12 was inserted into a flexible loop of DHFR 
that is inactivated and FKBP12 ligand FK506 rescues the activity of DHFR that leads to growth 
of the yeast (69). Similarly maltose binding protein was used a regulatory domain inserted into 
TEM1β-lactamase which response to maltose as it changes lactamase activity 600 fold (68). 
The insertion site was identified by an iterative in vitro recombination approach. 
While in vitro selection technologies may provide a route to build allosteric switches, 
structure- and sequence-based rational approaches may accelerate the design process. Using 
multiple sequence alignment information to calculate covariation between amino acid pairs, 
one can identify the residues that are coevolved and intrinsically coupled. In a proof-of 
principle study, LOV2 was inserted a site that is allosterically coupled to active site of DHFR 
whose activity slightly increased (1.6 fold increase in the hydride transfer rate) in the light (70). 
Although many examples of engineered protein switches have given some insights 
about the design rules, use of protein switches in living cells to study precisely regulated 
processes demand challenging additional requirements. Because even low background activity 
may saturate the behavior to be studied in the time scale of protein expression, the switch 
should have almost negligible background activity before the induction. The switch also should 
respond to stimuli by reaching the activity levels close to natural activity so that response can 
be captured. Such a robust switch was built for kinases that can be regulated with rapamycin 
(RapR). In this approach, insertion of engineered FKBP (iFKBP) turns off the host kinase 
almost completely, and addition of rapamycin rapidly rescues the kinase activity by 
stabilization of iFKBP through binding of FRB and rapamycin (71) (Figure 1.3). Since it may 
 28 
be challenging to control the stoichiometry of two components, thus a single chain version of 
RapR switch is required.   
 
Control of active site residues 
 Another strategy to cage activity of a protein is done by the substitution or modification 
of residues that are key for the activity, thus the distorted active site can be rescued with 
synthetic small molecules or light. For example, the function of a mutant kinase but not the 
wild type was perturbed using mutant specific inhibitors (72). Similarly, a mutant inactived 
Src kinase was rescued by imidazole to investigate the effect of Src kinase activation on MAPK 
pathway (73). Another example is a design of mutant zinc finger domain that is incapable of 
DNA binding to start the transcriptional activity unless it is bound to a non-natural small 
molecule that was identified through high-throughput screening (74). However, identification 
of small molecule for each mutant protein of interest can be a hurdle for the generalization of 
this approach. To use a common small molecule for different protein targets, a tryptophan 
residue neighbor to active site of β-glycosidase and GFP was replaced with a glycine that 
perturbs the active site (75, 76). To rescue the protein activity, tryptophan side chain indole 
was added to fill the “hole”, which is formed due to the tryptophan-glycine substitution, in the 
core of the enzyme. This approach is not broadly applicable, as it requires the presence of a 
tryptophan residue in the vicinity of active site.  
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(A) A key bulky residue important for the activity is substituted with a smaller amino acid, and 
then rescued with a small molecule. (B) A key residue is modified with a photo-cleavable 
group.  
  
 
 Modifying a key residue with a covalently bound photocleavable-protecting group is a 
common way to create a photoactivatable protein. Actin regulatory protein cofilin is caged by 
converting its serine at position 3 to cysteine and labeling it with the light cleavable group α-
bromo-(2-nitrophenyl) acetic. This modified cofilin mimics the inactive phosphorylated state, 
and upon light activation. It was found that cofilin polymerases actin, leads to protrusions and 
affects the navigation of cell migration (77). In another application, photolysis of the caging 
group partially leads to both activation and increase in fluorescence of cAMP-dependent 
protein kinase (78). Recently photoswitchable cadherin, which is functional when its bound to 
calcium, was built by conjugating photoisomerizable chromophore BSBCA to a calcium 
binding loop to control activity of cadherin by controlling its binding to calcium (79). 
Moreover, photoactivatable key cytoskeleton proteins including paxilin (80), focal adhesion 
kinase (FAK) (81), myosin light chain kinase (82) were built to investigate their precise roles 
in cell motility. 
 In the case of modification of a specific residue in a purified protein, synthetic 
approaches are limited by the size of the protein, and the location of the key residues have to 
be close to the terminals. Moreover, microinjection of in vitro modified protein is a technical 
Figure 1.4.   Chemogenetic and optogenetic control of active (key) residues 
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challenge, often resulting in cellular stress. On the other hand, genetic modification of key 
residues with light-cleavable caging groups was enabled through development of engineered 
orthogonal aminoacyl-tRNA synthetase/tRNA pairs (83). Examples include caged tyrosine of 
B-galactosidase (84), and DNA polymerase (85) in E.coli, topoisomerase Cre recombinase 
(86), T7 RNA polymerase (87), zinc finger nuclease (88) in HEK 293T cells, caged serine of 
transcription factor Pho4 (89) in Saccharomyces cerevisiae, and caged lysine in the active site 
of MEK1 (90). Further applications of these tools remain as an opportunity to interrogate the 
signaling pathways and associated cellular behaviors.  
 
Control of protein stability 
One of the first attempts to generically cage (inhibited in the initial state) a protein was 
to fuse the protein of interest to a mutant protein, which is engineered to be unstable. In result 
the chimeric protein is rapidly degraded by endogenous proteolysis machinery upon translation 
(Figure 1.5). Destabilized FKBP12 mutants and their fusion proteins were rescued from the 
degradation with rapamycin analogs (91, 92). A similar approach was also developed by using 
destabilized mutant of dihydrofolate reductase (DHFR), which can be rescued with its small 
molecule ligand trimethoprim (93). Similarly, mutant destabilized FRB (94) was used to reveal 
temporal windows of glycogen synthase kinase-3β function in midline development of mice 
(95). Although the use of this technology for processes occurring in fast time scales is 
indecisive, this tool was proven to be useful to study relatively slower time scales such as 
defining discreet stages of animal development (95).  
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A destabilized mutant protein A is fused to protein of interest (orange), resulting in degradation 
of the protein. Binding of a small molecule (pink) to the restabilized protein rescues the protein 
from the degradation. 
 
   
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5.   Control of protein stability 
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CHAPTER 2: RATIONAL DESIGN OF A LIGAND-CONTROLLED PROTEIN 
CONFORMATIONAL SWITCH1 
 
2.1 Introduction  
Design of a regulatable multi-state protein is a challenge for protein engineering. Here 
we design a protein with a novel topology, called uniRapR, whose conformation is controlled 
by the binding of a small molecule. We confirm switching and control ability of uniRapR in 
silico, in vitro and in vivo. As a proof of concept, uniRapR is used as an artificial regulatory 
domain to control activity of kinases. By activating Src kinase using uniRapR in single cells 
and whole organism, we observe two novel phenotypes consistent with its role in metastasis. 
Activation of Src kinase leads to rapid induction of protrusion with polarized spreading in 
HeLa cells, and morphological changes with loss of cell-cell contacts in the epidermal tissue 
of zebrafish. The rational creation of uniRapR exemplifies the strength of computational 
protein design, and offers a powerful means for targeted activation of many pathways to study 
signaling in living organisms. The past two decades have seen a revolution in computational 
protein design, with remarkable milestones including design of a helical protein from first 
principles (96), redesign of zinc finger proteins (97), and de novo design of an alpha/beta 
protein (98). 
 
1 This chapter previously appeared as an article in the Proceeding of the National Academy of Sciences. The 
original citation as follows: Dagliyan O. “Rational design of a ligand-controlled protein conformational switch 
Proceedings of the National Academy Sciences, 110 (April 2013): 17. 
 33 
 
These studies highlighted, as a proof-of-principle, our ability to rationally control the 
structure of proteins using basic physical principles and phenomenology. These approaches 
are based on finding an optimal sequence for a given single structure or ensemble of related 
states, and do not provide a strategy to construct a protein capable of large on-demand 
conformational transitions (99, 100). A number of multi-state protein design algorithms (99, 
101) have been proposed, however designing an experimentally confirmed, regulatable 
multistate protein, or a conformational switch (100), still remains as a challenging because of 
the necessity of engineering and controlling multiple protein states (99, 102, 103). 
Such a conformational switch protein has great advantages in cell signaling, because it 
can be used as a universal regulatory domain (104) for precise, specific and temporal control 
over rapidly activated signaling proteins (1, 44, 48, 70, 71, 100, 105). Traditional genetically 
encoded methods for temporal protein control at the protein level have several drawbacks (100, 
105). Recently developed protein switches, including derivatives of the LOV domain (36, 106), 
can provide direct control at the protein level with light, but cannot be readily employed in 
non-transparent animals. Our previous RapR kinase method (71) can potentially overcome this 
problem, but it requires expression and control of two proteins (Figure 1.3). The variable 
stoichiometry of these proteins renders the response more heterogeneous and essentially 
impractical in animals. Therefore, a single chain, insertable and transferable regulatory domain 
would be very valuable. 
Here we design a ligand-controlled conformational switch, uniRapR, a potentially 
broadly applicable, single chain regulatory domain. We first confirm its switching properties 
and control ability with molecular dynamics and in vitro enzymatic assays. Further, by 
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temporally activating Src kinase with uniRapR in living single cells and zebrafish, we reveal 
two novel phenotypes related to the role of this kinase in metastasis. activation.  
 
2.2 Results and Discussion 
Design of uniRapR with desired stability and conformational dynamics 
Design of ligand binding proteins is still an unsolved problem in protein design (107); 
therefore to design a ligand-controlled protein, we first utilize the binding pocket of one of the 
highest affinity (91) protein-ligand complexes, FKBP12-FRB in complex with rapamycin 
(108). We rationally rewired this complex to build a single chain protein featuring a new 
topology (109) (Figure 2.1A). To construct the subdomain-A of uniRapR, we utilized elements 
of insertable FKBP12 (iFKBP), a modified FKBP that we had previously demonstrated its 
insertion does not destroy the structure of a host protein (71). Subdomain-B of uniRapR 
contains the rapamycin-binding surface of FRB, and we stabilized this with two helices grafted 
from FRB. Thus, we expect the resulting design has all the desired properties of a universal 
regulatory domain featuring modularity, transferability, and robust switching ability. To test 
conformational switching features of uniRapR, we constructed a structural model of uniRapR 
(Figure 2.1B) based on complex structure of FKBP-FRB-rapamycin and performed replica 
exchange and equilibrium discrete molecular dynamics (DMD) simulations (110, 111). 
Previous studies using insertable FKBP had shown that the transition between a folded and 
unfolded state could be used to control kinase activity when the FKBP was inserted at a 
conserved site in kinases. Therefore, desired switching properties of uniRapR were achieved 
by manipulating the subdomain motions and changing the relative stability between the folded 
and unfolded states. 
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(A) The FKBP12 (blue)/FRB (green) complex was used to build the switch module. While 
keeping the sequence from ß2 to ß5 of iFKBP, we linked ß5 of subdomain A to the carboxy-
terminal α helix (α4) of subdomain-B using an optimized GS linker to permit a hinge-like 
motion.  Because the N-terminus of α1 is relatively close to the C-terminus of α4, we linked 
these two helices using a PPGPGSG linker. Sequences of helices α2 and α3 were kept as in 
wild type FRB, and α3 was linked to the C-terminal ß-strand (ß6) of subdomain A, since the 
N-terminus of ß6 of FKBP is in the vicinity of the ternary complex interface. (B) A model of 
the holo-uniRapR (blue: subdomain-A, green: subdomain (B) protein was built based on the 
crystal structure of the FKBP12/FRB complex (pdb: 1fap) using DMD. (C) Heat capacities of 
apo (red) and holo (black) forms of uniRapR were calculated using WHAM11. (D) RMSDs of 
apo (red) and holo (black) subdomain A were calculated for different temperatures using 
WHAM. (E) Distance between Cα atoms of amino and carboxyl termini as a function of 
temperature for apo (red) and holo (black) forms of uniRapR. (F) Relative positions of 
uniRapR subdomains compared to the FKBP12/FRB proteins in complex. Distance between 
centers of masses (CM) of uniRapR subdomains A and B was calculated using multiple 
molecular dynamics trajectories. In the presence of rapamycin (black), distance of CM of 
uniRapR subdomains is approximately 24 Å, close to that of FKBP12 and FRB complex 
(green). In the absence of rapamycin (red), uniRapR subdomains move randomly and they are 
not in contact.   
 
We estimated the stability of uniRapR states by characterizing its folding 
thermodynamics. We calculated its specific heat (Cv) and the root-mean-square deviation 
(RMSD) from the native structure of iFKBP as a function of temperature. A peak in the Cv 
curve (Tm) corresponds to the folding transition, indicated by significant increase of RMSD 
Figure 2.1.   Design and thermodynamics of uniRapR domain ation. 
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(Figure 2.1C and D). We observed the stabilization of uniRapR upon rapamycin binding as a 
shift in Tm to a higher temperature. UniRapR can achieve regulatory function when inserted 
into a host kinase because its thermal stability and a change in its equilibrium amino (N-) and 
carboxy (C-) termini distance are dependent on rapamycin binding. Indeed, we observed 
reduced distance between Cα atoms of N- and C-termini upon binding of rapamycin (Figure 
2.1E). Equilibrium simulations confirmed that subdomain-A only interacts with subdomain-B 
in the presence of rapamycin (Figure 2.1F). These observations suggest that the conformation 
of uniRapR depends on the presence of rapamycin, where binding of rapamycin to the pocket 
formed by the two subdomains stabilizes uniRapR. 
We hypothesize that uniRapR renders a protein switchable when inserted into a site 
that is allosterically coupled to its active site. Allosteric sites can be identified using 
information from experimental mutation studies in the literature or using various 
computational methods (112-114). We inserted uniRapR into the Src kinase at a site known 
(71) to be allosterically coupled to the ATP binding site (Figure 2.2A). In equilibrium DMD 
simulations, we observed that uniRapR inserted into Src at residue 288 with optimized double-
GPG linkers destabilized the ATP binding site through long-range interactions, suggesting 
inactivation of the kinase in the absence of rapamycin. Rapamycin binding to uniRapR reduced 
fluctuations in the G-loop (residues 276-279), which is part of ATP binding site. The reduced 
fluctuations in the presence of rapamycin restored the G-loop dynamics of Src-uniRapR to a 
level identical to that of wild type Src (Figure 2.2B), implying activation of the kinase in the 
presence of rapamycin. Computational analysis thus suggests that Src kinase activity can be 
regulated by inserting uniRapR at a position that is allosterically coupled to ATP binding site.  
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(A) Illustration Schematic representation of activity control with the uniRapR domain. (B) 
Root mean square fluctuations of the ATP binding site (gray structure) based on multiple 
equilibrium DMD simulations for wild type Src (black), apo (red), and holo (green) uniRapR 
inserted Src (p-value < 0.01). (C) HEK293T cells expressing the Src-uniRapR-cerulean-myc 
construct were treated with different concentrations of rapamycin (0 to 2µM) and lysates were 
assayed for expression of the construct with Western blotting using anti-GFP. The construct 
was pulled down with anti-myc and mixed with the paxillin substrate in the presence of ATP 
for 10 minutes. Reaction suspensions were blotted and probed with anti-myc and anti-pY31-
paxillin to confirm binding and phosphorylation of the substrate, respectively. (D) As controls, 
constitutively active Src (YF) without the uniRapR domain, kinase dead (YF/KD), Y271A and 
L1polyP Src mutants with the uniRapR domain, and our previous dimerization-based switch 
were tested. (E) Y271A and L1polyP substitutions shown on the Src-uniRapR modeltime.   
 
UniRapR enables specific and robust control over various kinases in vitro 
We tested uniRapR functionality in vitro using Src kinase expressed in human 
embryonic kidney (HEK293T) cells. Using paxillin as the Src substrate, we observed that 
constitutively active Src kinase (115) modified with uniRapR (uniRapR Src (YF)) 
demonstrated greatly enhanced activity in the presence of rapamycin, confirming that uniRapR 
functions as a specific on/off switch. Significantly, the uniRapR switch required only ~100 nM 
of rapamycin to activate Src-uniRapR (Figure 2.2C). A catalytically dead Src mutant (D546R) 
(116) with inserted uniRapR was inactive regardless of the presence of rapamycin, indicating 
that rapamycin-induced phosphorylation of paxillin is only due to Src-uniRapR catalytic 
Figure 2.2. Control of Src kinase activity with uniRapR domain. 
 38 
activity. Additionally, when we constrained the hinge motion of the uniRapR domain by 
substituting the optimized flexible linker (Figure 2.3) between subdomains with a rigid poly-
proline linker (uniRapR-L1P), catalytic activity in the presence of rapamycin was abolished 
(Figure 2.2D). Based on our model and on the crystal structure of the FKBP12/FRB complex 
showing that Y271 (Y82 in PDB code: 1fap) is in contact with rapamycin, we expected Y271A 
substitution to abolish rapamycin binding. We observed dramatically reduced activity of 
uniRapR Src (Y271A), further indicating that uniRapR Src switching activity is directly 
dependent on rapamycin binding to uniRapR Src (Figure 2.2D and E). Significantly, we 
observed that uniRapR Src has much higher switchable kinase activity than did our previous 
dimerization-based control of kinase activity (RapR), in which kinase activity was regulated 
using co-expressed wild type FRB and iFKBP (71) (Figure 2.2D). These results indicate that 
insertion of the uniRapR switch enables us to robustly and specifically control Src kinase 
activity. To assess the transferability of the uniRapR switch, we inserted uniRapR into 
analogous sites of focal adhesion kinase (FAK) and mitogen-activated kinase p38. Insertion of 
uniRapR into a constitutively active mutant (116) of FAK (YM) inhibited the activity of FAK 
(YM) for its substrate paxillin; addition of rapamycin rescued FAK activity (Figure 2.4A). 
Addition of rapamycin did not rescue kinase-dead FAK (YM/KD) activity, suggesting that 
rapamycin-induced phosphorylation of paxillin is only due to FAK-uniRapR activity. A design 
with a different circularly permuted version of uniRapR (Figure 2.5A) did not allow control of 
FAK activity (Figure 2.5B). Insertion of uniRapR into p38 kinase with the same linker (GPG) 
abolished its activity, which could be restored by the addition of rapamycin. Activity of wild 
type p38 was unchanged in the presence of rapamycin (Figure 2.4B).  
 39 
 
(A) Testing different lengths of double linkers between uniRapR subdomains. A double linker 
connecting the subdomains A and B were shown in red and cyan. The linker with asteriks is 
the one used in the current version of uniRapR. (B) Src-uniRapR-cerulean-myc constructs were 
expressed in HEK293T cells. Cell lysates were blotted with anti-GFP to confirm the expression 
of the construct. In dimerization-based switch (RapR), co-expressed FRB was also tested with 
anti-GFP. Cell lysates were pulled down with anti-myc and mixed with substrate paxillin in 
the presence ATP for 10 minutes. Reaction suspension was blotted with anti-myc to confirm 
the binding, with anti pY31-paxilin to confirm the phosphorylation of the substrate. The linker2 
is the one required for functional uniRapR. (C) The design with truncated linker 2 (linker 1) 
does not provide control over Src.   
 
Insertion of uniRapR into p38 with an optimized linker described in our previous study (71) 
resulted in a higher activity in the presence of rapamycin. Indeed, we observed activity similar 
to wild type in the presence of rapamycin (Figure 2.4B), indicating that optimal regulation of 
the host protein can be achieved by varying the connection linker. All these data suggest that 
uniRapR can be inserted as a transferable regulatory domain in a wide variety of kinases. 
Figure 2.3. Effect of different linkers on uniRapR-Src activity. 
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Specific activation of Src kinase leads to polarized spreading in single cells 
Signaling cascades containing Src kinase play important roles in cell growth, 
proliferation, migration, and tumor invasiveness (115). However, the specific roles of Src 
catalytic activity, especially in cell migration, are unclear due to the limitations of existing 
chemical and genetic methods, including limited temporal control of activation or inactivation. 
For example, overexpression of constitutively active Src prevents the observation of events 
immediately following Src activation, as the cell compensates for Src expression, probably 
with other Src kinase family members, during gradual increase in expression level. Likewise, 
blocking Src expression with RNA interference is also a slow process.  
 
(A) Immunoprecipitation, in vitro FAK (A) and p38 (B) assays were performed similarly as 
for Src kinase. (C) Change in cell area of HeLa cells expressing either Src (YF)-uniRapR (8/8 
cells) or Src (YF/KD)-uniRapR (8/8 cells). (D) HeLa cells expressing Src-uniRapR (YF)-
cerulean demonstrate spreading after the addition of rapamycin.   
 
 
Figure 2.4.   Testing uniRapR in other kinases and effects of Src activation in HeLa cells. 
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We overcome these limitations by using uniRapR Src (YF), which can reach maximal 
stimulation in less than 3 minutes. To observe the effect of Src activation on cell motility, we 
expressed uniRapR Src (YF) in HeLa cells. In the absence of rapamycin, we observed only 
peripheral ruffles near the cell edge, a phenotype also seen in untransfected cells. After 
rapamycin addition, we observed a statistically significant increase in cell area for all cells 
examined, relative to those expressing catalytically dead Src (YF/KD)-uniRapR (area increase 
= 30% ± 5 %, n = 8 cells; Figure 2.4C and D). Control cells showed no statistically significant 
change (area change = 8% ± 6 %, n = 8 cells). In a control study, rapamycin alone did not have 
any effect on the phenotype of untransfected cells. Polarized spreading of HeLa cells following 
Src-activation supports a role for Src in cell invasiveness.  
 
 
(A) A different design having different connections between secondary structure components 
do not provide any control over FAK, tested by biochemical assay (B).   
Figure 2.5. A negative design of a FAK switch 
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Specific activation of Src kinase causes loss of cell-cell contacts in zebrafish epidermis  
While we observe a profound impact of Src activation in cultured cells, it is crucial to 
determine whether uniRapR Src (YF) enables Src activation to be studied in the context of a 
multi-cellular organism. To study the role of Src activation during development, we expressed 
uniRapR Src (YF) in zebrafish embryos (Figure 2.6A). Epidermal cells expressing uniRapR 
Src (YF) demonstrated wild-type polygonal shape and formed tight connections with no 
gapping in the absence of rapamycin (Figure 2.6B). When we activated uniRapR Src (YF) by 
adding rapamycin, the epidermal cells had extended protrusions and underwent significant 
morphological changes in 12-16 hours. These morphological changes caused the loss of cell-
cell contacts as cells became more rounded (Figure 2.6C).  
     
(A) Synthetic transposase mRNA was co-injected with the Tol2 Krt4 Src (YF)-uniRapR-
cerulean plasmid into one-cell zebrafish embryos, resulting in mosaic expression of Src-
uniRapR in the epidermis. Epidermal cells with characteristic flat honeycomb morphology 
were selected and imaged before (B, F) and after (C, G) 16 hours of rapamycin treatment. (C) 
Epidermal cells expressing Src (YF)-uniRapR-cerulean in zebrafish embryos were exposed to 
10 µM rapamycin become rounded and undergo dynamic cell shape changes. White arrows 
indicate an epidermal cell before and after each treatment. Control epidermal cells expressing 
Src (YF)-uniRapR-cerulean in vehicle (DMSO) (D) or expressing the kinase-dead construct 
Src (YF/KD)-uniRapR-cerulean in rapamycin (G) have a static morphology and do not 
undergo dynamic cell shape changes. Scale bar 30 µm.   
 
 
Figure 2.6. Activation of Src induces cell changes in zebrafish epidermal cells. 
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In control experiments, we did not observe morphological changes when cells 
expressing uniRapR Src were treated only with vehicle (Figure 2.6D and E), or when we 
expressed the catalytically-dead uniRapR Src (YF/KD) construct in zebrafish embryos in the 
presence of rapamycin (Figure 2.6F and G), demonstrating that the observed effects are due 
specifically to uniRapR Src activation by rapamycin. This dramatic phenotype of altered cell 
morphology upon Src activation demonstrates the applicability of uniRapR in studying 
signaling pathways in whole organisms. 
 
2.3      Conclusion 
Design of a broadly applicable artificial regulatory domain has been challenging for 
the following reasons: (i) the protein should be able to adopt multiple states that can be” 
switched” by exogenous stimulation, i.e, ligand binding; (ii) the designed switch should be 
transferable, i.e., its action must be predictable and reproducible in a variety of host proteins; 
and (iii) the protein must be readily insertable into the host protein without significantly 
destabilizing it. We have solved these problems by designing a single chain protein that can be 
regulated by a small molecule. Control of activity via small molecule binding can be achieved 
by harnessing protein-protein interactions that occurs in the presence of ligands, for example 
ABll:absisic acid:PYL1 (117), or FKBP12:rapamycin:FRB (108). Here we use the 
FKBP12/rapamycin/FRB complex, because a photoactivable version of rapamycin is 
available, to potentially making uniRapR a tool for spatial as well as temporal control of protein 
activity (118). Also, non-immunosuppressive rapamycin analogs (119), such as iRap, can be 
employed for minimal perturbation of normal physiology in animal studies. The iRap was 
proven to be innocuous in living cells (4). Here we show that Src-uniRapR is also active in the 
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presence of iRap (Figure 2.7). UniRapR can potentially be applied to a wide range of rapidly 
activating, allosteric signaling proteins. The dynamic behavior of a particular protein in a 
signaling pathway can be investigated by using a uniRapR protein analog to activate the 
proteins with minute resolution. Moreover, by inserting uniRapR into putative allosteric loops 
in a protein of interest, allosteric sites that are coupled can be experimentally identified.  
 
The velocity of Src (CA)-uniRapR, Src(KD)-uniRapR in the presence of rapamycin, and non-
immunosuppressive rapamycin analog iRap.   
 
We selected Src kinase as a proof of concept system to be tested in HeLa cells and 
zebrafish tissue, because the specific role of this Src family member in cell motility is unclear. 
The roles of individual Src family members have proven to be difficult to dissect using 
traditional approaches, due to the functional redundancy and structural similarity of the Src 
family kinases (SFKs). SFKs are involved in many cellular processes including transcription, 
differentiation, proliferation, development, motility and cell death, and the majority of them 
have been identified as cellular oncogenes (115, 120). Using a uniRapR version of SFK 
Figure 2.7. Kinetics of uniRapR-Src with rapamycin and iRap 
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members including Yes, Fyn, Lyn, Lck, Hck, Blk, Fgr, and Yrk kinases, differential roles of 
these proteins in cell motility can ultimately be elucidated.  
An important advantage of uniRapR is its practical use in animals. Light-dependent 
control can be useful at the single cell level, but uniRapR can provide activity control with the 
small molecule rapamycin even within deep tissues, where light cannot penetrate. To 
investigate the effect of Src kinase activation on a higher order process such as intercellular 
communication in animals, a significant process involved in tissue development, repair, 
immune response and homeostasis (115, 120), we tested uniRapR Src in living zebrafish 
epidermal tissue. We demonstrated that activation of Src kinase leads to a decrease in 
communication between cells, consistent with its oncogenic role in metastasis. The dynamic 
behavior of proteins downstream of Src, for example Connexin 43 or Cas that are involved in 
inter-cellular communication (121), will be the subject of future study.  
UniRapR is a unique example of an insertable, transferable, and ligand-controllable 
protein switch. This switch has widespread potential applications for understanding signaling 
pathways involving kinases, a glimpse of which is offered by the novel phenotypes we 
demonstrate in mammalian cells and zebrafish tissue upon Src kinase activation. The 
potentially wide applicability of uniRapR is underscored by the structural conservation of 
kinases, and the allosteric properties of many signaling proteins. 
 
2.4      Materials and Methods 
DNA construction 
All restriction enzymes were purchased from New England Biolabs. All site-directed 
mutagenesis and gene insertion experiments were performed with the QuikChange 
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mutagenesis kit (Stratagene). PCR products were used as mega-primers for QuikChange 
mutagenesis reactions (Supplementary Table 1). The uniRapR domain was created using PCR 
such that the 5′- and 3′-end sequences anneal at the desired insertion site within the Src, FAK 
and p38 genes. 
 
Modeling of uniRapR and Src-uniRapR structure 
To model uniRapR, we removed first twenty residues from FKBP12 (PDB code: 1fap) 
using PyMol (http://www.pymol.org/), so that the two termini are close in space for insertion. 
We built a circularly permuted FRB, by excising at Asn2093 and joining the N- and C-termini 
together. We removed first four unstructured residues of FRB and connected the two termini 
with a peptide linker (PPGPGSG). In order to build a single chain protein, we excised FKBP12 
in Pro88 and connected FRB-G2092 to FKBP12-Gly89 and FKBP12-His87 to FRB-Val2094 
with corresponding linkers. We optimized the complex structure by minimizing the energy 
using all-atom DMD simulations. We kept the unmodified regions of FKBP12 and FRB 
molecules static, whereas linkers were allowed to move to sample conformation and form 
peptide bonds under the peptide bond constraints1 between FKBP12/FRB and linkers.  
Similarly, we modeled Src-uniRapR by excising the catalytic domain of Src at peptide 
bond of N287-G288 (PDB code: 1Y57) and joining the termini of Src insertion loop and 
uniRapR with corresponding linkers, GPG. We used the model structures after energy 
minimization to perform either replica exchange simulations to characterize the folding 
thermodynamics, or constant temperature simulations to probe the conformational dynamics. 
To model the rapamycin-bound state, we applied constraints between rapamycin and 
subdomain-A similar to interactions of rapamycin with FKBP12 in the crystal structure. 
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Computational analysis of uniRapR 
We perform all-atom DMD simulations to study the conformational dynamics of 
uniRapR. A complete description of the discrete molecular dynamics (DMD) algorithm can be 
found elsewhere (122, 123). We performed replica exchange DMD simulations to estimate the 
folding thermodynamics. We used eighteen replicas with temperatures ranging from 0.52 
kcal/mol·kB (~260K) to 0.75 kcal/mol·kB (~390K), with an increment of 0.02 kcal/mol·kB 
(0.01 kcal/mol·kB between 0.64 kcal/mol·kB and 0.72 kcal/mol·kB). The length of each 
simulation is 1 × 106 time units (~50ns). We applied the weighted histogram analysis method 
(124) (WHAM) to estimate thermodynamic properties of the uniRapR domain. Next, we 
computed the partition function, Z=∫ρ(E)exp(−E/kBT)dE, which allowed us to derive other 
thermodynamic parameters, including the specific heat (Cv) at different temperatures. We also 
calculated RMSD and tail distance of subdomain A as function of temperature using WHAM 
analysis. 
We performed a constant temperature simulation of Src-uniRapR at 0.5 kcal/mol·kB. 
This is below the folding transition temperature of uniRapR, thus the inserted domain stays 
folded while the DMD simulation optimizes its relative orientation with respect to Src. We 
computed distances between centers of masses of uniRapR subdomains for multiple 
trajectories. Similar to subdomain-A insertion into subdomain B, we applied peptide bond 
constraints to insert uniRapR into Src kinase and performed equilibrium DMD simulations. 
We computed normalized dynamic correlation matrices (113) to determine the Src activation 
mechanism. To exclude protein drift when computing residues’ fluctuations correlations and 
root mean square fluctuations (RMSF), we translated the center of mass of the protein to the 
origin and aligned each snapshot with respect to the average structure. 
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Immunoprecipitation and in vitro kinase assay 
Anti-myc and anti-FLAG antibodies were purchased from Millipore and Sigma, 
respectively. Anti-phospho-paxillin-pTyr31, anti-GFP (JL8) antibodies were purchased from 
Biosource and Clontech, respectively. Anti phospho-ATF2 was purchased from Santa Cruz. 
Rapamycin was purchased from Sigma. HEK293T cells were transfected with 2 µg of DNA 
constructs using Fugene6 reagent (Roche). Cells were treated with either rapamycin or an 
equivalent volume of ethanol (solvent of rapamycin solution). Cells expressing Src or FAK 
constructs were then washed with cold PBS and lysed with 20 mM HEPES-KOH, pH 7.8, 50 
mM KCl, 100 mM NaCl, 1 mM EGTA, 1% NP40, 1mM NaF, 0.1 mM Na3VO4, and Roche 
protease inhibitor cocktail.  Cells expressing p38 were lysed with 20 mM Tris, pH 7.5, 150 
mM NaCl, 1 mM EGTA, 1mM EDTA, 1% Triton X-100, 0.5% NP40, 20mM NaF, 0.2 mM 
Na3VO4, and Roche protease inhibitor cocktail. Cells treated with rapamycin were lysed with 
the appropriate lysis buffer containing the corresponding rapamycin concentration. Cleared 
lysates were incubated with protein-G beads attached to anti-myc (for Src and FAK) or anti-
FLAG (for p38) antibody for 2 hours. The beads were washed three times with wash buffer 
(20 mM HEPES-KOH, pH 7.8, 50 mM KCl, 100 mM NaCl, 1 mM EGTA, 1% NP40), and 
then with kinase buffer (25 mM HEPES-KOH, pH 7.5, 5 mM MgCl2, 0.5 mM EGTA, 0.005% 
BRIJ-35) for Src and FAK assays. For p38 assays, beads were washed with p38 lysis buffer 
and then with p38 kinase buffer (25 mM HEPES-KOH, pH 7.4, 10 mM MgCl2, 25 mM beta-
glycerophosphate, 4 mM dithiothreitol (DTT), 0.1 mM Na3VO4).  For Src and FAK assays, 20 
µl of bead suspension were used in the presence of purified substrate paxillin (0.05 mg/ml), 
and co-substrate ATP (0.1 mM). For p38 assays, 1µg purified ATF2 and ATP (0.5 mM) in 40 
µL of kinase buffer were mixed with bead suspension for the reaction. 
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Live cell imaging 
HeLa cells were plated on fibronectin coated coverslips (10 mg/ml fibronectin for 1 
hour at 37 ºC, Sigma) and then incubated for 3 hours. DMEM (with 10%FBS) medium was 
then replaced with L-15 imaging medium (Invitrogen) supplemented with 5% FBS. An open 
heated chamber (Warner Instruments) was used to maintain the cells. Live cell imaging was 
performed with an Olympus IX-81 microscope equipped with ZDC focus drift compensator. 
Images were collected using a PhotometrixCoolSnap ES2 CCD camera (Roper Photometrics). 
Metamorph software (Molecular Devices) was used to control the microscope, and to acquire 
and process images at each time point. To calculate cell area, each cell was manually traced 
around its edge, and a binary mask was created using Metamorph. Values were normalized to 
be 1 at the time point before addition of rapamycin. 
 
Imaging of live zebrafish 
Approximately 5 nl of a DNA-RNA solution containing 20 ng/µl circular DNA of a 
transposon-donor plasmid and 40 ng/µl transposase mRNA were injected into one-cell 
zebrafish embryos. Twenty-four hours after the injection, individual embryos with epidermal 
expression of Src were imaged before and after 16 hours of exposure to 10 µM rapamycin 
(Invitrogen) or vehicle (DMSO). Only epidermal cells with characteristic flat honeycomb 
morphology were selected for analysis, due to the fact that robust transgene expression induces 
cell defects before treatment. Imaging was performed on a confocal microscope (FluoView 
FV1000, Olympus). 
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CHAPTER 3: CHEMOGENETIC PAK1 SWITCHES ENABLE SPECIFIC 
ACTIVATION OF A PAK ISOFORM IN CELL MOTILITY 
 
3.1. Introduction 
 p21-activated kinases (PAKs) have been associated with cell motility and morphology, 
yet it has been challenging to interrogate functions of individual PAK isoforms in living cells 
due to non-specific actions of PAK inhibitors and activation of compensatory pathways upon 
genetic manipulations. Here we engineer a genetically encoded, ligand-sensitive analogue of 
the isoform PAK1 that enables allosteric and selective kinase activation in living cells. We 
show the mechanism of allosteric control at a single-residue level through identified 
propagation pathways from the perturbation site to the active site. Our analysis on structural 
and dynamic features of the kinase domain also reveals alternate allosteric pathways that were 
exploited to generate versatile kinase switches. In order to capture consequences of PAK1 
activation on cell motility, we turn on this switch in various living systems. Activation of PAK1 
results in transient cell spreading in metastatic human breast cancer cells. Interestingly, in 
mouse hippocampal CA1 neurons, PAK1 activation leads to persistent dendritic spine 
enlargement. These results underscore the context-dependent roles of PAK1 in cell motility, 
and also suggest design routes to make various allosteric protein switches for controlling 
spatiotemporal dynamics of kinases. 
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 p21-activated kinases (PAKs), consisting of six members (PAK1-6), are 
serine/threonine kinases involved in many cellular processes including cell growth, death, 
survival, proliferation, differentiation, motility and polarity (125). PAK is a key regulator of 
cytoskeleton networks, as its activity has been associated with protrusions (126-128), 
dissolution of stress fibers and loss of focal adhesions (129), control of adhesion turnover and 
strength (10, 129, 130). Such major cytoskeletal roles render PAK particularly relevant in 
various motility-driven biological processes including cancer metastasis (131), angiogenesis 
(132), synaptic transmission (24, 133, 134), and neurogenesis (135). However, these studies 
remain to be correlative; it is unclear how PAK dynamically contributes to cell motility, and 
the requirement of its kinase activity in motility remains controversial (125, 126, 136). 
 PAK inhibitors offer potential to interrogate dynamic roles of PAK in living systems, 
and to treat several disorders including certain types of cancer (131, 137) and schizophrenia 
(138). However, target specificity of these inhibitors is debated; thus, it remains uncertain 
whether a particular PAK isoform is responsible for a suggested mechanism. We decided to 
apply our RapR and uniRapR technologies in order to selectively activate a PAK1 isoform 
However, in contrast to the monomeric kinases we previously targeted (71, 139, 140), PAK is 
a homodimer in its inactive state (88), hence it is not obvious whether this method would be 
applicable to PAK. Here we engineer novel PAK switches and revealed the effects of its kinase 
activity on cell motility in breast cancer cells and hippocampal neurons.  
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3.2 Results and Discussion 
Engineering and optimization of a dual chain PAK1 switch 
 We decided to focus on the PAK1 as a proof of concept, because it is the dominant 
isoform upregulated in human tumors, and it is one the three isoforms (PAK1-3) expressed in 
brain. Similar to other PAKs, PAK1 consists of a kinase domain and regulatory domains 
including p21-binding domain (PBD) for the localization and PAK inhibitory domain (PID) 
for the regulation of activity. In order to control directly the kinase activity, we targeted the 
kinase domain in our both dual and single chain PAK1 switch designs (Figure 3.1A and B). 
Dual-chain design has unique capabilities to turn on the switch at a particular subcellular 
location or to guide the switch to a target molecule. Single-chain design conveniences the 
delivery of the construct and guarantees equal expression of iFKBP and FRB. The insertion 
site for the kinases used in our previous studies indicates that our ligand sensitive allosteric 
domains (iFKBP and uniRapR) can be inserted into the loop between residues 288 and 293 in 
PAK1. This loop is not evolutionary conserved, indicating it is not essential for the function of 
protein (Figure 3.2). Also, this loop neither interacts with the regulatory domain nor with the 
dimerization interface (Figure 3.1C). Our structural analysis also showed that this loop is 
surface exposed and it does not interact with any other structural elements in the protein (Figure 
3.3A), indicating a proper insertion site for our allosteric domains. 
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(A) Dual chain (rapamycin regulatable or RapR) PAK1 switch was built by inserting insertable 
FKBP (iFKBP) domain into the catalytic domain. The system requires co-expression of FRB. 
(B) Single chain (unimolecular rapamycin regulatable or uniRapR) PAK1 switch was built by 
inserting insertable uniRapR domain into the catalytic domain. This system does not require 
co-expression of FRB. (C)  Crystal structure of PAK1 in inactive state. Auto-inhibitory domain 
(AI) and p21 binding domain (PBD) are shown with salmon and green, respectively. Insertion 
sites are red residues shown with black arrows. (D) Rapamycin dependent activity of 
constitutively active (CA) PAK1, kinase-dead (KD) PAK1, RapR-PAK1, and uniRapR-PAK1. 
(E)  Area and (F) perimeter of MDA-MB-231 cells that stably express uniRapR-PAK1 before 
and after addition of rapamycin.   
 
 
 We first sought to design a dual chain PAK1 switch, and replaced the insertion loop 
with the iFKBP domain (Figure 3.1A and Figure 3.3). In order to increase the activation effect, 
we introduced phospho-mimetic S422D/T423E mutations into PAK1 to render it constitutively 
active. We substituted residue 288 in the insertion loop with the iFKBP and a double GPG 
linker, which was used for other RapR kinases.  We co-expressed this construct (288 GPG) 
with FRB in HEK293T cells. Following immunoprecipitation of PAK1, we tested the kinase 
activity using a PAK1 substrate, MEK1, which is phosphorylated at residue S298 by PAK1 
(136). Addition of rapamycin led to almost negligible activation of PAK1 (Figure 3.3).  
Figure 3.1. Engineering genetically encoded PAK1 switches 
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(A) Residues used for insertion are not conserved. (B) Conservation of the kinase domain, 
represented by sequence entropy, mapped on the structure.  
 
 
 Next, we targeted the next residue 289 in the same loop and substituted this residue 
with iFKBP either with a G-linker or GPG-linker. Remarkably, we observed almost full PAK1 
activation upon addition of rapamycin (Figure 3.3B). FRB was present in pull-down samples, 
indicating the binding of FRB to PAK1-iFKBP. We further increased the dynamic range of 
activation by substituting entire loop with iFKBP. We termed this version as rapamycin 
regulatable PAK1 (RapR-PAK1). As a control experiment, constitutively active (CA) PAK1 
alone did not respond to rapamycin, whereas kinase-dead (KD) PAK1 alone was inactive in 
the absence or presence of rapamycin (Figure 3.3B). All these experiments demonstrated that 
Figure 3.2. Sequence conservation of PAK1 kinase domain 
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insertion of iFKBP domain into the loop between residues 288 and 293 generates a robust 
PAK1 switch. 
 
 
(A) Structure of PAK1 dimer and residues in the insertion loop. (B) Biochemical in vitro test 
of various RapR-PAK constructs.   
 
 
Single chain PAK1 switch in triple negative breast cancer cells 
 We made a single chain version of RapR-PAK1 by replacing iFKBP with the uniRapR 
domain (uniRapR-PAK1). We directly compared RapR-PAK1 and uniRapR-PAK1 by 
monitoring the phosphorylation state of endogenous MEK1 upon addition of rapamycin into 
the cell media. Similar to the behavior of RapR-PAK1, uniRapR-PAK1 was inactive without 
rapamycin and rapidly activated by rapamycin (Figure 3.1D). We further increased the 
Figure 3.3. Insertion loop and optimization of linkers 
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dynamic range of uniRapR-PAK1 by introducing another mutation L107F (141) that blocks 
dimerization and enhance activity of PAK1. These results showed that both dual and single 
chain PAK1 switches could be rapidly activated in living cells by rapamycin.  
 PAK1 was identified as a breast cancer oncogene that transforms breast epithelial cells 
(142). Moreover, overexpression of mutant PAK1 was shown to increase migration rates of 
breast cancer cells (143). In order to demonstrate direct effects of PAK1 kinase activity in 
breast cancer cells, we expressed uniRapR-PAK1 in highly metastatic triple-negative breast 
cancer cells MDA-MB-231. We measured the area and perimeter of cells after 5, 20, and 60 
minutes of rapamycin addition. Remarkably, cell area and perimeter had a transient increase 
upon addition of rapamycin (Figure 3.1E and F). After such a rapid spreading, cells went back 
to their original morphology at the 20-minute time point. Control cells exhibited no response 
to rapamycin. These results indicated that catalytic activation of PAK1 resulted in transient 
spreading; suggesting metastasis signaling circuits have additional requirements for persistent 
spreading in addition to PAK1 activity. 
 
PAK1 activation results in persistent dendritic spine enlargement 
 Surprising transient effects of PAK1 kinase activation in triple negative breast cancer 
cells led us to investigate PAK1 kinase activity in other living systems. PAK1 is expressed in 
axons and dendrites in hippocampal and cortical neurons (144, 145), and constitutively active 
mutant is enriched in dendritic spines (146). Our previous findings in mice hippocampus 
showed that prolonged photo-activation of upstream Rac1, which is an activator of PAK1, 
leads to shrinkage of dendritic spines (147). Thus, we asked whether persistent activation of 
PAK1 leads to same morphological change.   
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(A) Image of RapR-PAK1-Venus in a dendrite. (B) A series of RapR-PAK1-Venus images in 
a dendrite before and after stimulation with rapamycin (2.5 µM), which was applied in the 
period between 0 and 15 min. (C) Volume changes of two spines (#1 and #2) indicated in (B). 
The changes were estimated from the total fluorescence of RapR-PAK1-Venus in the spines. 
(D) Mean time courses of spine volume obtained from 33 or 13 spines in either RapR-PAK1-
Venus or EGFP along with FRB-mCherry transfected neurons. Error bars indicate SEM. (E) 
Statistical comparisons of the effects of rapamycin (2.5 µM) shown in (D). *p < 0.05, **p < 
0.01.   
 
 
 We expressed RapR-PAK1-EGFP in hippocampal CA1 neurons (Figure 3.4A), and 
surprisingly observed that activation of PAK1 led to persistent dendritic spine enlargement 
(Figure 3.4B). Although each spine responded to rapamycin with different kinetics (Figure 
Figure 3.4. Enlargement of dendritic spines induced by rapamycin 
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3.4C), there was an overall persistent increase in the spine volume (area of change 60% ± 15%, 
n = 35 spines), whereas neuron expressing only EGFP did not respond to rapamycin (n = 13 
spines) (Figure 3.4D and E). Based on these results, we concluded that activation of PAK1 
leads to persistent dendritic spine enlargement.   
 
Allosteric propagation in PAK1 can be maintained through alternative pathways  
 What are the rules to make a kinase switch? We hypothesize that loops that move in 
concert with the active site can be an insertion site for the allosteric domain, as perturbation of 
the insertion site would be propagated to the active site. Additionally, we select loops that are 
surface exposed or not in contact with the rest of the protein. We analyzed the molecular 
dynamics of PAK1 kinase using discreet molecular dynamics (111, 123). Indeed, motions of 
the insertion loop (L1) correlate with the catalytic site, particularly the ATP binding site 
(Figure 3.5A). Using the same analysis, we also identified another loop (L2) whose motions 
correlate with the motion of ATP binding site. Similar to L1, this loop is also solvent exposed 
and is not evolutionarily conserved (Figure 3.5B). 
 In order to test whether L2 loop is permissive to generate an allosteric switch, we 
substituted residues G337 and D338 in L2 with uniRapR domain. Similar to the original PAK1 
switch (uniRapR-PAK1-L1), the uniRapR-PAK1-L2 switch responded to rapamycin 
immediately (Figure 3.5C). We further reduced the slight off-state activity by removing two 
more residues from the loop, V336 and E339 (Figure 3.5C). These results along with the results 
of linker optimization of the first switch showed that the activity range can be adjusted through 
the linkers. Off-state activity can be reduced by shortening the loop or removing residues from 
the insertion loop, and off-state can be increased by elongating the loop using flexible residues. 
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Overall, a PAK1 switch can be generated by inserting uniRapR into the loops whose motions 
correlate with the motions of catalytic site. 
 
 
(A) Correlative motions of residues in PAK1 kinase domain. Correlation map of the kinase 
domain. Red denotes correlation, while blue denotes anti-correlation between two residues. b. 
Network representation of kinase domain based on contacts (<5.5Å). Gray nodes represent 
residues; edges represent the contacts. L1 is the canonical insertion site and L2 is newly 
identified insertion site. Red arrows represent the propogation pathways to ATP binding site 
(yellow node). (C) Insertion of uniRapR to both insertions sites confer rapamycin-mediated 
control. In the second version of L2 based switch (uniRapR-PAK1-L2-v2), loop residues from 
PAK1 removed, resulting in a tighter control. (D) Suggested mechanism of L1 based switch. 
(E) Suggested mechanism for L2 based switch. (F) Summary of the mechanisms of PAK1 
switches.   
 
 
 How is the propagation transmitted from the insertion loop to the active site? We 
hypothesize that residues that move in concert in the kinase domain may constitute the same 
Figure 3.5. Computational design to generate versatile PAK1 switches 
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allosteric path, which can be responsible for the propagation. In order to track potential 
propagation pathways, we performed a network analysis by converting motion dynamics of 
residues into an undirected network, in which nodes represent residues, edges represent 
contacts, and edge weights are assigned based on correlation coefficients calculated by 
molecular dynamics simulations (Figure 3.5B). 
 
 
Co-evolved residues of PAK1 kinase domain were identified using MISTIC (148). 
 
 
 The shortest path from insertion loops L1 or L2 to the catalytic site was calculated 
using Dijkstra’s algorithm (149). We observed that the propagation from L1 is transmitted 
through the strands located between residues G293-Q300 and G282-D289 (Figure 3.5C). 
Interestingly, such intra-strand propagation is not present in the case of L2, where the 
perturbation is propagated in an inter-strand manner between strands E91-E97, G45-N54, G34-
Figure 3.6. Residues that are co-evolved with L1 and L2 loops 
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D41, and E26-D41 (Figure 3.5D and E). As an alternative approach, we analyzed potential 
allosteric pathways using co-evolution of residues (148). Identification of residues that co-
evolve with the catalytic site indicated a similar inter-strand pathway (Figure 3.6). All these 
results showed that perturbation is propagated from our canonical (L1 insertion), which was 
used in our previous work, and non-canonical (L2 insertion) insertion loop via intra-strand and 
inter-strand manner, respectively.  
 
3.3     Conclusion 
 Here we engineer PAK switches that are turned on by rapamycin or its non-
immunosuppressive analogs. We previously showed that non-immunosuppresive analogs also 
bind both uniRapR and iFKBP domains, thus we also expect that our PAK1 switches can be 
activated by such analogues. We classify our PAK1 switches as “conformational switches”, 
meaning that an inducer controls the conformation of the protein. This type of tool has unique 
advantages; such as substantially low activity before being switched on. In contrast to many 
other tools, that are designed to control localization of protein activity rather than its 
conformation, can be used for certain proteins which are only active in certain subcellular 
region. However, PAK1 is involved in many subcellular regions in the cell, and our approach 
does not intervene with its normal localization. An alternative way to study PAK1 in rapid and 
dynamic processes would be using PAK inhibitors. Like other kinase inhibitors, many PAK 
inhibitors, which are ATP-competitive molecules, are not very selective. An allosteric 
inhibitor, IPA-3 was designed to bind amino-terminal regulatory domain group 1 PAKs, yet 
undesired toxic effects in cells and unselective binding with PAK1-3 renders these inhibitors 
problematic.  
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 We focus on PAK1 as a target protein, because its role in cytoskeleton remains 
controversial, and to our knowledge, there is currently no PAK1 switch in the literature. Many 
of the previous studies included overexpressed constitutively active or dominant negative 
PAKs. These studies suggest that overexpression of constitutively active PAK leads to large 
and polarized lamellipodia, whereas expression of dominant negative PAK leads to multiple 
random lamellipodia in fibroblasts (127). Nevertheless, overexpression of constitutively active 
kinases can increase intracellular signaling above the physiological basal state. On the other 
hand, studies that used acute activations through injection of constitutively active PAK1 into 
the cells report rather different phenotypes (126, 136). Because PAK1 is upregulated in 
metastatic breast cancer, we first tested phenotypic effects of PAK1 in highly metastatic MDA-
MB-231 cells. PAK1 activation caused transient spreading, suggesting that other pathways are 
required for a persistent metastatic behavior of these cells. 
 In addition to its association to metastatic breast cancer, PAK1 is involved in basic 
neuronal behaviors. PAK1 is implicated in synaptic transmission, spine morphology, and 
several pathological conditions such as mental retardation and schizophrenia. but 
consequences of its kinase activity is unclear. The kinase activity of PAK is important, because 
PAK inhibitors have been shown to ameliorate schizophrenia-associated dendritic spine 
deterioration (150). However, these inhibitors are not isoform specific, thus it remains unclear 
which isoform is responsible for the observed effect. Upstream of PAK1, GTPase Rac1 has 
been suggested as a key regulator in modulation of neuronal activity. We and other previously 
showed that activation of Rac1 in vivo leads to spine shrinkage in hippocampus  (147, 151). 
Here we find that activation of PAK1 leads to spine enlargement in CA1 hippocampal 
pyramidal neurons. This observation suggests that Rac1 mediated memory erasure is mediated 
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by PAK1 independent mechanisms. These results may give insight into the roles of PAK1 in 
long-term-potentiation, learning and memory. 
 Our analysis on propagation mechanisms revealed that the perturbation is allosterically 
propagated through the beta strands located between G293-Q300 and G282-D289 in our 
canonical switch designs. This observation is expected as destabilization of a loop in a 
structural unit such as beta-strand perturbs other residues in the same strand. However, we 
observed an inter-strand allosteric propagation in our second type of design. Such an allosteric 
propagation is meaningful, because correlated motions in B-sheets have been suggested to be 
fundamental for allosteric regulation of protein function (152). Understanding propagation 
mechanisms in our allosteric switches will be helpful to generate novel switches not only for 
different kinases but also for other protein families.  
 
3.4 Materials and Methods 
DNA constructs 
All restriction enzymes were purchased from New England Biolabs. Point mutations 
and insertions of iFKBP and uniRapR sequences into PAK1 cDNA were done with 
Quikchange mutagenesis kit (Stratagene). Retroviral plasmids were generated by cloning 
uniRapR-PAK1-mCherry into pBABE-Tet-Off-puro plasmid (Clontech). 
 
Biochemical characterizations 
Anti-myc antibody were purchased from Millipore. Anti-pMEK-S298 and anti-
MEK1/2 from X. Anti-GFP (JL8) was purchased from Clontech. Rapamycin was purchased 
from Sigma. HEK293 cells were transfected with 1 µg of DNA constructs using Fugene6 
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reagent (Roche). After 24 hours of transfection, cells were treated with either rapamycin or an 
equivalent volume of ethanol for 30 minutes. Cells were lysed with lysis buffer (20 mM 
HEPES-KOH, pH 7.8, 50 mM KCl, 100 mM NaCl, 1 mM EGTA, 1% NP40, 1mM NaF, 0.1 
mM Na3VO4, and Roche protease inhibitor cocktail). Endogenous phosphorylation of MEK 
was detected by western blotting. For immuniprecipitation experiments, cleared lysates were 
incubated with protein-G beads attached to anti-GFP antibody for 2 hours. The beads were 
washed three times with wash buffer (20 mM HEPES-KOH, pH 7.8, 50 mM KCl, 100 mM 
NaCl, 1 mM EGTA, 1% NP40), and then with kinase buffer (25 mM HEPES-KOH, pH 7.5, 5 
mM MgCl2, 0.5 mM EGTA, 0.005% BRIJ-35) for phosphorylation assays. Purified ATF2 and 
ATP (0.5 mM) in 40 µL of kinase buffer were mixed with bead suspension for the reaction for 
10 minutes. Phosphorylated MEK was detected in pull-down samples by western blotting.  
 
Imaging of MDA-MB-231 cells 
After allowing 2 days without doxcyline in the media, cells were seeded at 10,000 cells 
per well in DMEM with puromycin on fibronectin coated coverslips (10µg/ml). The next 
morning (about 6 hours before the experiment), cell media was replaced with to the DMEM 
(2% FBS) with 450µl in each well of a 4 well plate. Cells were incubated with 500 nM of 
rapamycin for 5, 20, and 60 minutes. Cells were then fixed in 4% PFA (in PBS) and stained 
with DAPI (1:10000) and phalloidin Alexa488 (1:1000). Cells were imaged with a Olympus 
IX71 inverted microscope.  
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Imaging of mouse hippocampal cells 
Hippocampal slices with a thickness of 350 µm were prepared from 7-day-old Sprague-
Dawley rats. Slices were mounted on 0.4-µm culture inserts (Millipore, Billerica, MA) and 
incubated at 35°C under 5% CO2 in a medium consisting of 50% MEM (Invitrogen, Carlsbad, 
CA), 25% Hanks’ balanced salt solution (Invitrogen), 25% horse serum (Nichirei, Tokyo, 
Japan), and glucose (6.5 g/l) (Nacalai Tesque, Kyoto, Japan). After 4 days in culture, the slices 
were transfected with a Gene Gun system (PDS-1000; Bio-Rad, Hercules, CA) with RapR-
PAK-Venus and FRB-mCherry. Imaging experiments were performed 3 days after the 
transfection. Each culture insert was transferred to a recording chamber and superfused with a 
solution (ACSF) that contained 125 mM NaCl, 2.5 mM KCl, 2 mM CaCl2, 1 mM MgCl2,1.25 
mM NaH2PO4, 26 mM NaHCO3, 20 mM glucose, 1uM TTX, and 200uM Trolox, and had been 
equilibrated with 95% O2 and 5% CO2. Rapamycin (Wako, Tokyo) was applied through bath 
perfusion. All physiological experiments were performed at room temperature (23° to 25°C). 
The experiments were approved by the Animal Experiment Committee of the Faculty of 
Medicine, University of Tokyo. Two-photon imaging of dendritic spines was performed with 
an upright microscope (BX61WI; Olympus, Tokyo, Japan) equipped with a FV1000 laser-
scanning microscope system (FV1000, Olympus) and a water-immersion objective lens 
(LUMPLFLN60xW, numerical aperture 0.9). We use a mode-locked, femtosecond-pulse 
Ti:sapphire lasers (MaiTai from Spectra Physics, Mountain View, CA; Chameleon from 
Coherent, Santa Clara, CA) with a wavelength of 970 nm. Emitted fluorescence was acquired 
at 488 to 560 nm and 590 to 680 nm for Venus and mCherry, respectively. 
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Modeling, discrete molecular dynamics, and correlative motion analysis 
Crystal structure of the kinase domain was obtained from Protein data bank (PDB id: 
1f3m). Medusa Toolkit was used to model the protein (153). All simulations were performed 
using all-atom discrete molecular dynamics (154). Atomic clashes were corrected and the 
protein was minimized at heat exchange coefficient 10 at 0.7 kcal/mol·kB with harmonic 
potential constant of 1 kcal/mol•A2.  The system was then packed without any constraint at 0.3 
kcal/mol·kB with heat exchange coefficient 1. Upon packing, the system was simulated at 0.4 
kcal/mol·kB for 1 million DMD steps.   
 
Monitoring propagation and dynamic networks 
The network was built using the Cα atoms which are represented as nodes of the graph, 
and edges represent the contacts between residues. Edge weights were assigned based on the 
correlation coefficient of motions calculated using discreet molecular dynamics. The shortest 
distance between two selected residues were calculated by Dijkstra’s algorithm (149). 
 
Sequence conservation and co-evolution analysis 
Pfam (155) was used to obtain the sequences of the kinase domain family. MISTIC 
server (148) was used to calculate the sequence conservation and co-evolved residues. 
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CHAPTER 4: COMPUTATIONAL DESIGN OF SPLIT PROTEINS TO CONTROL 
PROTEIN ACTIVITY 
 
4.1      Introduction 
Split protein reassembly methods have been valuable for visualization of protein 
activity in living cells. However, the design of split proteins for protein control has been 
challenging due to spontaneous assembly, and inefficient induction of effective reassembly. 
Here, we introduce a generalized approach, termed split protein reassembly enabled by ligands 
or light (SPELL), to predict split sites using a novel scoring function (split energy), prevent 
spontaneous assembly, and facilitate efficient reassembly of the split parts using an engineered 
domain. The split proteins can be controlled by light or a small molecule. Our analysis of 16 
known split proteins shows that functional split sites can be predicted using the split energy. 
Moreover, our engineered domain enables destabilization of split proteins, thus preventing 
spontaneous assembly of the split protein before activation. We apply SPELL to a new target, 
the catalytic domain of the guanine exchange factor Vav2, and demonstrate that its activation 
modulates the protrusion dynamics of living cells. The SPELL methodology offers new 
opportunities to interrogate dynamics of previously untargeted proteins. 
Rapid and localized control of protein activity in living cells is a valuable approach to 
probe how the spatio-temporal dynamics of protein activity controls cell behavior. Chemical 
and optical dimerizers, proteins that are induced to interact with each other by a ligand or light, 
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have been used to control protein localization and interactions (3, 4, 27, 38). However, such 
approaches have limited effectiveness in that they typically generate activity only at specific 
subcellular locations. Controlling protein conformation has been accomplished by inactivating 
the target protein using inducible domains, and then restoring its activity rapidly with light or 
ligands (36, 46, 48, 59, 139, 156). However, these proteins and those under the control of 
dimerizers often show some level of activation before they are switched on (43). 
Another strategy to achieve protein control has been to inactivate proteins by splitting 
them into two parts, rendering them inactive, and then inducing reassembly for activation (157). 
Despite the extensive use of such split-protein approaches to make fluorescent biosensors (158), 
controlling protein activity through splitting has been limited by several critical challenges. 
First, it is difficult to predict an appropriate split site. Second, there can be high basal activity 
of split proteins in the absence of an inducer due to spontaneous protein reassembly, and third, 
activity can be diminished with respect to wild type protein upon induction, due to misfolding 
of reassembled protein or low efficiency of reassembly. Most successful split protein designs 
have been generated by splitting at linkers that connect two separate domains (both necessary 
for activity) which we will term “easy targets”. Proteins that have single catalytic domains may 
be considered “hard targets”. Few split protein analogues of such targets have been generated, 
and these have required extensive experimental screening approaches. For both hard and easy 
targets, in some cases the interface of the split parts have been further engineered to reduce 
spontaneous assembly or to increase the efficiency of reassembly (159, 160). 
To address these challenges, we propose a methodology, split protein reassembly 
enabled by ligands or light (SPELL), that includes identification of the split sites in proteins 
using a novel scoring function termed “split energy”, prevention of spontaneous assembly using 
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an engineered domain, and efficient ligand- or light-mediated reassembly of the split parts. We 
first investigated existing split proteins to assess the accuracy of our method, and then applied 
SPELL to a new “hard” target that has a single catalytic domain. 
 
4.2      Results and Discussion 
Split protein reassembly enabled by ligands or light (SPELL) 
We first assumed that splitting a protein at a surface-exposed loop would enable the split 
parts to fold and reassemble. Unless the split parts irreversibly misfold, the structural integrity 
of periodic secondary structures would be preserved. To identify appropriate loops that are 
likely to tolerate sequence variation (161) and do not interact with other sites of the protein, we 
first compute the solvent accessible area and that sequence conservation of each residue in the 
target protein (Figure 4.1A). However, accomplishing this step does not guarantee correct 
folding and intact split parts, as the split parts may not have the minimum structural elements, 
e.g. folding nucleus, to fold into their unique three dimensional structures. We therefore propose 
a new scoring function, the “split energy”, which is an energetic descriptor to assess the effect 
of splitting on the stability of the protein. To compute the split energy, we computationally split 
the protein at each residue and calculate the total energies of the split parts with respect to the 
native energy of the intact protein. Such a metric enables quantification of the destabilization 
energy for any residue. We propose that the split energy profile of a given protein may show 
either a single well minimum, indicating a single protein core, or multi-well minima suggesting 
multiple domains or “hidden subdomains” with multiple cores. We hypothesize that appropriate 
split sites are located in loops that are distant from the core indicated by minima, as splitting 
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within cores may unfold the split parts irreversibly. In the multi-well minima case, the protein 
can be split either at interdomain and subdomain loops or at sites with minimum effect on the 
core of the major split parts (Figure 4.1A). 
While a split energy profile predicts potential split sites, it does not eliminate the 
possibility that split parts may spontaneously reassemble. We propose that spontaneous 
assembly can be inhibited by using insertable FK506 binding protein (iFKBP, our engineered 
derivative of FKB506 binding protein (FKBP)) (71), which can be inserted into the split part 
containing the dominant core (for the single domain case), or either domain or subdomains (for 
the multi-domain case) (Figure 4.1B). iFKBP is an ”insertable” derivative of the FKBP domain 
(71) in which the N-terminus is truncated to bring the N- and C-termini close together. Upon 
addition of the membrane-permeable drug rapamycin (or non-immunosuppressive analogs (4)), 
the FRB and iFKBP domains heterodimerize. Our molecular dynamics simulations showed that 
truncation of the N-terminal β-strand from FKBP12 to generate iFKBP decreased the melting 
temperature by 5 degrees, and the energy of the refolded iFKBP increased significantly 
compared to that of FKBP12. Therefore, use of iFKBP in split proteins can destabilize the split 
parts, and assist in their efficient reassembly, as the iFKBP N-terminus is less than ~7 Å from 
the C terminus of FRB in the rapamycin bound FRB-iFKBP heterodimer (Figure 4.1C). We 
propose that use of this domain will prevent spontaneous reassembly and increase the efficiency 
of reassembly (Figure 4.1B). 
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(A) Identification of the split site by computing solvent accessible area (surface exposure), 
sequence conservation, and energy change upon splitting from residue i, where 1≤ i≤ N. The 
selected loop was marked with a green box. (B) Prevention of spontaneous assembly with 
insertable FKBP (iFKBP), which destabilizes the core lobe. (C) Structural model of iFKBP-
FRB-rapamycin system. The N terminus of iFKBP is fused to the C terminus of target protein’s 
N-lobe, whereas the C terminus of the FRB is fused to the N terminus of C-lobe of the target 
protein.   
 
 
Computational prediction of split sites on GFP 
  To test the accuracy of the split energy, we first analyzed existing split proteins. Split 
green fluorescent proteins (GFPs) have been extensively used to detect protein-protein 
interactions, and multiple split sites have been suggested and tested (158). GFP has a single 
domain with 11 β-barrels, and an α-helix containing the covalently attached chromophore in 
the center. Our analysis of sequence conservation and surface exposure of GFP suggested 10 
potential loops as split site candidates (Figure 4.2A).  When we computed a split energy profile, 
Figure 4.1.  Protocol of SPELL. 
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it surprisingly suggested the presence of two hidden subdomains (Figure 4.2A and B), not 
detectable from visual inspection of the structure. 
 
(A) Loops, solvent accessible area (SAA), sequence conservation (cons), consensus of these 
three parameters (loop, SAA cons), and split energy. X axis = amino acid number. Dashed lines 
in the split energy profile show the experimentally tested successful (green) and unsuccessful 
(red) split sites. (B) Prediction of transition temperatures based on heat capacity and average 
root mean square difference (RMSD) with respect to initial structure. (C) Root means square 
fluctuations (RMSF) and contact numbers of GFP at different temperatures. Green arrows 
indicate experimentally tested successful sites. bp: break point. (D) Structure of GFP (pdb id: 
20yg) with computed core residues (blue spheres), and the experimentally tested successful 
(green) and unsuccessful (red) split sites. N-lobe = gray and C-lobe = salmon.   
 
  Prediction of such a multi-subdomain structure was not possible using contact numbers 
alone, underlining the necessity to consider energy contributions for the prediction. 
Figure 4.2.   Computational identification of split sites for GFP. 
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Experimentally successful split sites (at residues 129, 145, 158) (162) are located between these 
subdomains, supporting our argument about the conditions necessary for a split site (Figure 
4.2B). Specifically, residue 158 is in proximity to the second energy well, keeping the first core 
intact (Figure 4.2A). These results show that the split energy predicts functional split sites in 
GFP.  
  The split energy detected split sites on a static structure. We next tested whether the 
same split sites could be identified by investigating protein dynamics. We performed molecular 
dynamics simulations (111, 154) of GFP at different temperatures (Figure 4.2C) and estimated 
protein dynamics using root mean square fluctuations (RMSF) and contact numbers. Local 
minima in such unfolding energy diagrams suggested that the possible folding core residues are 
mostly located in the region between the N-terminus and the loop in residues 128-133 (Figure 
4.2D). The unfolding curve showed a remarkably sharp transition starting after this loop and 
reaching to the C terminus, suggesting a less stable region compared to the N-lobe, and a split 
site after such a breaking point. Indeed, the experimentally validated sites were after this 
predicted breaking point (Figure 4.2D). These results show that both the split energy profile 
and unfolding curves obtained by molecular dynamics simulations predict the split sites in GFP. 
 
Split energy predicts critical sites to split proteins 
We analyzed 15 other proteins whose split protein analogues have been previously 
generated. Consistent with our results above, the majority of split proteins have split sites in 
the proximity of interdomains and subdomains (GFP, IFP, DHFR, lactamase, Lyn kinase, 
ubiquitin, firefly luciferase, Renilla luciferase, aminoglycoside phosphotransferase, 
hygromycin phosphotransferase B, adenylate cyclase, Cas9 nuclease, Cre recombinase) 
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(Figure 4.3). Split sites close to the core of TEV protease and phosphatase result in only 40% 
and 65% of wild-type activity, respectively (163, 164). The split energy profile of Cre 
recombinase features two minima. The experimental split was performed within a loop in the 
first small domain to prevent spontaneous assembly. This site produces only moderate activity 
upon assembly (165), indicating a potential distortion of the core of the first domain.  
 
Split energy profile for each known split protein. Red lines represent unsuccessful split sites in 
the original work.  Dark green lines represent the most successful split site, whereas light green 
lines represent less successful (low activity upon reassembly) split sites.   
 
 
In split Cas9, the most successful split sites are inter-domain sites, although split sites 
close to the ends of domains of Cas9 (166) provide moderate activation. For single subdomain 
proteins (N-anthranilate isomerase, mutase), split sites are distant from the core and close to 
Figure 4.3.   Computational identification of split sites in 15 split proteins. 
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termini. These observations all suggest that the dominant core in the protein should be 
preserved for an efficient split design. 
 
SPELL Vav2 and control of cellular protrusion signalling  
To validate our approach, we targeted the Rho family guanine exchange factor Vav2, 
a protein that has not been previously controlled by splitting. As a crystal structure of Vav2 is 
not available, we generated a homology model of Vav2 based on the crystal structure of Vav1 
(167).  Using the split energy profile, we predicted a single subdomain architecture, making 
the catalytic Dbl homology (DH) domain of Vav2 a hard target to split (Figure 4.4A). 
Unchanged split energy on the loop around residue 345 (L4) pointed to a potential split site 
there. We fused the N-lobe of split Vav2 with iFKBP, and the C lobe with FRB (Figure 4.4B).  
To test the activity of this split protein in living cells, we used Rac1 FLARE.dc (168), a Rac1 
FRET biosensor that should be activated by Vav2 (Figure 4.4C). The Rac1 biosensor switched 
to its active state upon increasing co-expression of constitutively active Vav2 (Figure 4.4D). 
We next tested the ability of iFKBP to prevent spontaneous reassembly. Co-expression 
of the DH domain C-lobe fused to FRB either with the N lobe alone or with the N lobe fused 
to FKBP showed a significant background activity, indicating spontaneous reassembly of the 
split parts (Figure 4.4D). However, when we used iFKBP, no background activity was 
observed, indicating that the destabilizing ability of iFKBP was playing the desired role in 
preventing spontaneous assembly. Addition of rapamycin led to rapid and robust activation of 
Vav2 SPELL (Figure 4.4E). As an alternative method, we used a fluorometer to measure the 
spectra of Rac1 emission from cell suspension and observed that magnitude of FRET emission 
peak is increased significantly upon addition of rapamycin. To control SPELL Vav2 activation 
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using light, we employed our photo-activatable rapamycin, pRap (23), and showed that Vav2 
SPELL was active upon exposure of cells with a brief period of light (1 minute). Activation of 
Vav2 SPELL in HeLa cells induced protrusions within minutes as visualized by both increased 
area and non-uniform spreading (Figure 4.4F-I).  
 
(A) Energy profile of DH domain of Vav2 upon splitting from residue i, where 195≤ i≤ 390. 
Green box and arrow show the least destabilized region and chosen loop for splitting, 
respectively. (B) Model of Vav SPELL. iFKBP (light gray) was fused to C terminus of N lobe 
of DH (green), and FRB (dark gray) was fused to N terminus of C lobe of DH (blue) in the 
presence of rapamycin (purple).  (C) Dual chain Rac1 FRET sensor (Rac1 FLARE.dc1g) is in 
high FRET state when Rac1 is active, in low state when Rac1 is inactive. (D) FRET state 
(activity) of Rac1 with respect to amount of spVav-FKBP12-FRB (mCherry-DHN-FKBP12 
and FRB-DHC-PH-ZnF), Vav2 SPELL (mCherry-DHN-iFKBP and FRB- DHC-PH-ZnF), 
spVav-FRB (mCherry-DHN and FRB- DHC-PH-ZnF), and Vav (mCherry-DH-PH-ZnF). (E) 
Testing Vav2 SPELL with rapamycin and caged rapamycin. (F) A representative HeLa cell 
expressing Vav2 SPELL after 19 minutes of rapamycin addition. Green and red areas indicate 
the protrusions and retractions, respectively. Morphological changes of cells expressing Vav2 
SPELL (green, mean ±  s.e.m., n=19 cells), and cells expressing only membrane marker (black, 
mean ± s.e.m., n= 36 cells) were quantified for (G) normalized area, (H) protrusive activity, 
and (I) change in the polarity.   
 
 
Cells reached maximum protrusion activity within ten minutes (Figure 4.4H). This was 
consistent with Vav’s known role activating Rac1 to produce protrusions and motility (169). 
Figure 4.4.   Activation of SPELL-Vav leads to rapid protrusions. 
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These live cell studies showed activation through no detectable background activity, and 
robustly activated protrusions either through addition of rapamycin or light-activation of a 
ligand. 
 
4.3      Conclusion 
We developed a novel methodology providing a rational route to control protein 
activity through protein splitting and reassembly. This approach is substantially different than 
previous strategies, which relied on experimental screening of random split libraries (170) or 
insertion of long flexible linkers into candidate split sites (171). In some published cases, such 
as split ubiquitin, substitution of key amino acids at the interface of the split parts was used to 
prevent spontaneous assembly (159); such extensive engineering has hindered broad 
applicability. 
The first step of our approach includes the use of a novel scoring function that employs 
the structure or homology model of the protein of interest and a force field (153) to estimate 
the energy of split proteins. Splitting at each residue hypothetically provides an energy profile 
that indicates the protein core, a the set of key interactions required for protein folding (172). 
Surprisingly, the split energy suggested alternative cores, which we term hidden subdomains. 
We propose that splitting at sites that perturb the core would irreversibly unfold split parts, and 
therefore propose to split proteins such that one split part has most of the core, and to further 
destabilize this split part using iFKBP. This strategy both guarantees reassembly of split parts 
and reduces background activity. The N and C termini of iFKBP and FRB are oriented so that 
they can be appended onto the appropriate termini of the split protein halves, positioning the 
iFKBP/FRB pair and the protein halves appropriately for reassembly (Figure 4.1C). This 
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advantage reduces the effort required to optimize the linkers between the ligand/light gated 
domains and the split protein. 
 
 (A) Crystal structure of ITSN (red) and homology model of Vav2 (gray). (B) Normalized 
emission of Cdc42 sensor co-expressed with SPELL ITSN. 
 
We selected Vav2 as a proof of principle system, because it has a compact catalytic 
domain consisting of six helices that can be considered as a hard target to split.  Vav2 has been 
suggested to be a requirement for cell spreading based on overexpression studies (173), and 
here we directly showed that activation of Vav2 leads to rapid cell spreading in living cells. As 
there are currently no potent and selective Rho GEF inhibitors, controlling activity of Vav2 
using SPELL technology also suggests new means to control other Rho GEFs and potentially 
other proteins that have proven to be difficult to split. Indeed, we generated SPELL Intersectin1 
(ITSN), a Cdc42 GEF, tested its activity using Cdc42 FLARE DC1g, a Cdc42 biosensor (168), 
and found that SPELL ITSN is rapidly activated upon addition of the inducer (Figure 4.5). 
Figure 4.5.   SPELL Intersectin 
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The SPELL approach provides a versatile algorithm to activate a protein in living cells 
with either a membrane-permeable ligand or light, in addition to providing a design route to 
finding optimal split sites in the target, especially for hard targets such as single catalytic 
domains that may require extensive experimental screening. SPELL also eliminates the 
background problem that has hindered application of conventional chemical or optical 
dimerizers, and other split proteins. 
 
4.4     Materials and Methods 
 
Calculations of solvent accessible area, sequence conservation, secondary structures, and split 
energies 
Solvent accessible area and secondary structure were calculated using Stride (174). 
Sequences of protein families were obtained from Pfam (155) to calculate sequence 
conservation. For the proteins that did not have structures in the protein data bank, we built 
homology models using I-Tasser (175). To generate split energy profiles, target proteins were 
hypothetically split from residue i, where 1≤ i≤ N and N is the total number of residues. For 
each splitting event, split energy was calculated using the equation EN-(EA+EB). The energy of 
native structures (EN) and split parts (EA and EB) were calculated using our MEDUSA scoring 
function (153).  
 
Generation of unfolding curves 
Energies of crystal structures or homology models were first minimized using short 
discreet molecular dynamics simulations (154, 176) at high temperature (0.7 kcal/mol•kB) and 
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high heat exchange coefficient of 10, with a harmonic potential constant of 1 kcal/mol•A2. 
Systems were packed at low temperature (0.3 kcal/mol•kB) with a heat exchange coefficient of 
1 and electrostatic interactions between charged residues, including acidic and basic residues. 
Integer charges to the central atoms of charged groups were assigned as: CZ for Arg, NZ for 
Lys, CG for Asp, and CD for Glu. Debye-Hückel approximation was used to model screened 
charge-charge interactions. By assuming a monovalent electrolyte concentration of 0.1 mM, 
the Debye length was set at 10 Å. Relative permittivity of water was assigned as 80. 
Continuous electrostatic interaction potential was discretized with an interaction range of 30 Å, 
where the screened potential approached zero. The simulation time for production runs of each 
trajectory at each temperature was approximately 50 ns. To identify the melting temperatures, 
heat capacities at constant volume (Cv) and root mean square deviations (RMSD) at each 
temperature were calculated. Unfolding curves for each trajectory were generated by 
computing the root mean square fluctuations (RMSF) and contact number at each temperature. 
A simulation of each system at each temperature included ten independent trajectories. 
 
DNA constructs 
All restriction enzymes were purchased from New England Biolabs. Full length (FL) 
Vav2 and its Dbl homology (DH), pleckstrin homology (PH), and zinc finger domain (ZnF), 
or DH-PH-ZnF (176-575) domains were cloned into pmCherry-C1 plasmid (Clontech) using 
BspeI and MfeI sites. Vav2 was split as follows: Vav(FL) SPELL had the N lobe Vav(1-346) 
and C lobe Vav(348-868), whereas Vav(DH-PH-ZnF) SPELL had the N lobe Vav(176-346) 
and C lobe Vav(348-575). The N lobe of either Vav(FL) or Vav(DH-PH-ZnF) was fused to 
the C terminus of FLAG-mCherry and cloned into the pTriex4 plasmid at the Ecor1 and Not1 
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sites. Either FKBP12 (ARIAD Pharmaceuticals) or iFKBP was cloned into the C terminus of 
the N lobe with a short linker (GGSGGAAA) using the Not1 and Xho1 sites. Similarly, FRB 
(ARIAD Pharmaceuticals) was cloned into the pTriex4 plasmid at Ecor1 and Not1 sites with 
myc peptide at the N terminus. At the C terminus of this construct, the C lobe of Vav2 was 
cloned with the same linker used in the iFKBP-Vav N-lobe construct. In order to use a single 
plasmid that generates a fixed stoichiometry of the split parts, the two parts (N lobe with iFKBP 
and C lobe with FRB constructs) were combined into a single pTriex4 plasmid using t2a and 
p2a ribozyme skipping sequences (177). SPELL ITSN was constructed similarly. Components 
of the dual chain Rac1.DC.FLARE (Ypet-PBD and dTurq-Rac1) were also cloned into a single 
pTriex4 plasmid with t2a and p2a sequences. Cdc42.DC.FLARE was generated similarly. 
 
Synthesis of photo-caged rapamycin 
Photo-caged rapamycin was synthesized as previously described (23). 
 
High-content live cell FRET assays 
High-content live cell FRET imaging was performed as described previously (178). 
Briefly, we seeded the cells on 96-well plates and transfected the cells with biosensors, GEFs 
or controls using the Lipofectamine and Plus reagent (Invitrogen) as suggested by the 
manufacturer’s manuals. This assay generated dose response curves to evaluate the effect of 
each construct at different expression levels. We used an automated microscope to image each 
well at CFP, YFP, FRET, and mCherry channels. We used a custom-written Matlab script for 
image analysis that included calculation of the sum of pixel intensities at each channel, 
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background subtractions, bleedthrough corrections, and normalization of FRET to donor for 
each plate.  
 
Fluorometer assays 
HEK 293T cells were transfected using Lipofectamine (InVitrogen) according to 
manufacturer’s instructions. 24 hours post-transfection, cells were either treated with ethanol 
(vehicle) or rapamycin for 30 minutes. Cells were detached using trypsin, and resuspended in 
phosphate-buffered saline and placed in a fluorometer cuvette. The cells were analyzed using 
a Fluorolog SPEX 168 fluorometer. Samples were excited at 433 nm and emission was 
collected from 450 to 600 nm. To normalize for biosensor concentration, YFP was directly 
excited at 505 nm and its emission at 525 nm was measured. All measurements were 
normalized to CFP peak value.     
 
Live single cell imaging 
HeLa cells were plated on coverslips coated with 5 mg/mL of fibronectin (Sigma). 
Cells were transfected with Fugene, and incubated in DMEM growth medium supplemented 
with 10% (vol/vol) FBS at 37°C for 24 hours. L15 imaging medium (Invitrogen) supplemented 
with 5% (vol/vol) FBS was used for imaging. An open heated chamber (Warner Instruments) 
was utilized during live cell imaging, which was performed with an Olympus IX-81 
microscope equipped with an UPlanFLN 40x objective (Pil, N.A 1.30). Photometrics 
CoolSnap ES2 CCD camera (Roper Photometrics) was used to collect images. Metamorph 
software (Molecular Devices) was used to control the microscope and acquire images at each 
time point. Images were obtained at 1 min time intervals.  
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Image processing 
A custom-written Matlab script was used to quantify morphological changes in cells 
(179, 180). First, the cell boundary was detected using the MovThresh module, which 
automatically determines an intensity threshold for each time frame. For the images that were 
not detected automatically, threshold values were assigned manually.  The Proactive module 
was used to display and quantify protrusion activity and cell area. The Squigglymorph module 
was used to calculate the polarity index, which was calculated by detecting protrusion and 
retraction using pairwise comparisons of cell boundary points. The Squigglymorph module 
then places the distribution of protrusion boundary points on a circle, and quantifies the 
boundary movements using the polarization vector P(t), according to the equation: 
𝑃" 𝑇 = !D n( ) cos 2πnN!"# $%&n=1N∑ v n( )n=1N∑ , !D n( ) sin 2πnN!"# $%&n=1N∑ v n( )n=1N∑()* +,-  
𝑃%(𝑇) = 12𝑤 + 1 𝑃"(𝑇 + τ)-./0-  
where w is the half-width of the averaging window, v n( )n=1
N
∑  is the total number of protruding 
points, ( ) ( ) ( )[ ]nDnDnD yx ,=
!
 is length of the polarization vector formed by summation of 
displacement vectors of protruding boundary points. The sums of the areas associated with 
regions of the cell that undergo local extensions between subsequent frames were calculated. 
Such protrusive activity was then divided during each time interval by the time average 
protrusive area before the addition of rapamycin.
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